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Background: Prostaglandin (PG) E2 plays a critical role in colorectal cancer (CRC) progression, including epithelial-
mesenchymal transition (EMT). Activity of the rate-limiting enzyme for PGE2 catabolism (15-hydroxyprostaglandin
dehydrogenase [15-PGDH]) is dependent on availability of NAD+. We tested the hypothesis that there is intra-
tumoral variability in PGE2 content, as well as in levels and activity of 15-PGDH, in human CRC liver metastases
(CRCLM). To understand possible underlying mechanisms, we investigated the relationship between hypoxia, 15-
PGDH and PGE2 in human CRC cells in vitro.
Methods: Tissue from the periphery and centre of 20 human CRCLM was analysed for PGE2 levels, 15-PGDH and
cyclooxygenase (COX)-2 expression, 15-PGDH activity, and NAD+/NADH levels. EMT of LIM1863 human CRC cells
was induced by transforming growth factor (TGF) β.
Results: PGE2 levels were significantly higher in the centre of CRCLM compared with peripheral tissue (P = 0.04).
There were increased levels of 15-PGDH protein in the centre of CRCLM associated with reduced 15-PGDH activity
and low NAD+/NADH levels. There was no significant heterogeneity in COX-2 protein expression. NAD+ availability
controlled 15-PGDH activity in human CRC cells in vitro. Hypoxia induced 15-PGDH expression in human CRC cells
and promoted EMT, in a similar manner to PGE2. Combined 15-PGDH expression and loss of membranous E-
cadherin (EMT biomarker) were present in the centre of human CRCLM in vivo.
Conclusions: There is significant intra-tumoral heterogeneity in PGE2 content, 15-PGDH activity and NAD+
availability in human CRCLM. Tumour micro-environment (including hypoxia)-driven differences in PGE2 metabolism
should be targeted for novel treatment of advanced CRC.
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Colorectal cancer (CRC) remains the third most common
cancer worldwide with more than one million new cases
reported in 2008 [1]. The liver is the most common site of
CRC metastasis with 50-60% of CRC patients eventually
developing liver disease [2]. Metastasis, in common with
growth and invasion of established tumours, is dependent
on tumour cells acquiring a migratory and invasive* Correspondence: M.A. Hull@leeds.ac.uk
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reproduction in any medium, provided the orphenotype as part of a highly conserved cellular trans-
differentiation programme, the epithelial-mesenchymal
transition (EMT) [3,4]. Prostaglandins (PG), in particular
PGE2, have previously been implicated in EMT of CRC
cells [5].
Prostaglandins (PG) are fatty acid signaling molecules
known to have a range of physiological functions includ-
ing vascular homeostasis, reproduction and immune
regulation [6]. PGE2 is the most abundant PG in the
human colon and levels of PGE2 are increased in colo-
rectal neoplasia compared with normal colorectum [7].
Elevated PGE2 levels are known to promote colorectal
carcinogenesis at various stages, including CRC growthLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in promotion of EMT in vitro [8]. PG G/H synthase
(also known as cyclooxygenase [COX]) controls the
rate-limiting step in PGE2 synthesis, upstream of PGE
synthases [6]. There are two COX isoforms; the consti-
tutive isoform COX-1 and the inducible isoform COX-2,
which is up-regulated in CRC and is a putative target for
anti-CRC therapy [9,10]. Nicotinamide adenine di-
nucleotide (NAD+)-linked 15-hydroxyprostaglandin de-
hydrogenase (15-PGDH) controls the rate-limiting step
in PGE2 catabolism by conversion of PGE2 to 15-keto-
PGE2 coupled to the reduction of NAD+ to NADH [11].
Initial studies suggested that 15-PGDH expression is
reduced in bladder cancer, lung cancer and CRC
compared with paired normal tissue and has tumour
suppressor properties [12]. However, subsequent reports
have highlighted elevated 15-PGDH expression in breast
and ovarian cancer [12]. Moreover, there are conflicting
data on 15-PGDH expression in gastric cancer [12]. Het-
erogeneity of 15-PGDH expression in human cancers
may reflect tissue-specific differences in regulatory
pathways upstream of 15-PGDH [12], but may also be
related to sampling variation secondary to intra-tumoral
genetic and micro-environmental influences on 15-
PGDH expression [13,14].
There has been relatively little investigation of changes
in 15-PGDH activity, as opposed to gene expression, in
human cancer. Although NAD+, and its phosphorylated
form NADP, act as critical hydride-accepting co-
enzymes in cellular metabolism, NAD+ is also a sub-
strate for three classes of NAD+ −consuming enzymes,
which are the poly(ADP-ribose) polymerases (PARPs),
cADP-ribose synthases and sirtuins, expression and ac-
tivity of which can be altered in cancer cells [15,16].
Therefore, a valid hypothesis is that NAD+ availability is
rate-limiting for 15-PGDH activity and PGE2 catabolism
in CRC cells.
Regional hypoxia is common in many cancers includ-
ing CRC [17], in which established markers of tumour
hypoxia have been linked to worse prognosis [18].
Central tumour areas are believed to be more hypoxic
than peripheral tumour tissue [19] as demonstrated
in CRC liver metastases (CRCLM) by dynamic con-
trast-enhanced magnetic resonance imaging [20] and
immunohistochemistry (IHC) for carbonic anhydrase IX
[21]. Hypoxia is associated with increased PGE2 produc-
tion and release by several human cell types, including
human CRC cells, in vitro [22-24]. This is believed to
occur via induction of the COX-2-PGE synthase axis, with
no change in 15-PGDH expression, although 15-PGDH
activity and NAD+/NADH levels were not measured in
these studies [23,25]. Expression of NAD+ −consuming
enzymes such as SIRT1 is increased in hypoxic cells [26]
and overall NAD+ levels have been demonstrated to bereduced in ischaemic tissue, as well as a reduction in the
NAD+/NADH ratio [27].
Given the potential micro-environmental influence of
hypoxia and co-factor availability on PGE2 metabolism,
we tested the hypothesis that there are regional
differences in PGE2 levels within human CRCLM, which
are related to differential expression and activity of 15-
PGDH and COX-2 within tumours. To this end, we
collected and analysed human CRCLM tissue from per-
ipheral and central areas of tumours in a systematic,
protocol-driven manner, comparing our tissue findings
with observations in human CRC cells in vitro, including
those from the LIM1863 human CRC cell model of
EMT.
Methods
Detailed methodological descriptions are available in
Additional file 1: Methods.
Tissue collection
Approval for the study was obtained from the Leeds
(East) Research Ethics Committee. Tissue was retrieved
from 20 patients undergoing a first liver resection for
CRCLM at the Hepatobiliary Unit at St James’s Univer-
sity Hospital, Leeds between March 2007 and April
2008. A minimum tumour diameter of 3.5 cm in all
dimensions was required so that tissue from clearly
defined central and peripheral regions could be obtained.
Patients on regular (defined as more than two doses per
week in the previous month) aspirin or non-aspirin non-
steroidal anti-inflammatory drug (NSAID) therapy were
excluded, as were any patients who had received any
form of cytotoxic chemotherapy in the preceding three
months. Fresh tumour tissue was dissected in the oper-
ating theatre according to a strict protocol (Figure 1)
and samples were immediately placed on ice, prior to
immediate further processing or analysis.
PGE2 assay
Tissue PGE2 levels were measured using a competitive
immunoassay (Amersham Biosciences). Total protein
was measured using a Bradford protein assay kit (Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK). Data are
presented as pg PGE2 per mg total protein. PGE2 levels
in cell-conditioned medium are presented as pg per cell
number.
Immunohistochemistry
Immunohistochemistry (IHC) for 15-PGDH, COX-2 and
E-cadherin was performed on 5 μm sections of
formalin-fixed paraffin-embedded CRCLM tissue, which
included peripheral and central tumour regions
(Figure 1). COX-2 IHC was performed as previously
described by the Hull laboratory [28] using a rabbit
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Figure 1 Retrieval and processing of human CRCLM tissue. Diagram showing the dissection method for obtaining CRCLM tissue (light grey)
from a liver resection specimen (dark grey). A) A slice of tissue (dark rectangle) incorporating both central and peripheral tumour, as well as a rim
of surrounding liver, was obtained for fixation in formalin and subsequent embedding in paraffin wax. B) Tumour orientation and the location of
the centre of the tumour were confirmed with at least four other radial incisions (dashed arrows). Six peripheral tumour samples (each
approximately 0.5 cm3) were taken from within 0.75 cm of the tumour margin (marked P) taking care not to include any liver parenchyma or
tumour capsule. Similar sized central tumour samples (marked C; n = 6) were then taken from an area at least 1.5 cm from the peripheral samples.
Samples were immediately transferred to ice for assay or into liquid nitrogen for storage at −80°C.
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Immunohistochemistry for 15-PGDH and E-cadherin is
described in Additional file 1: Methods. All slides were
counterstained with haematoxylin. Negative controls
were prepared by omission of the primary antibody.Quantitative immunohistochemistry analysis
A computerized scoring method was developed to ensure
objectivity in selecting central and peripheral tumour
regions of interest and to quantify immunoreactivity in
each region of interest (see Additional file 1: Methods and
Additional file 2: Figure S1). Immunostained slides were
digitized using a Scanscope XT (Aperio, Vista, CA, USA)
and then analysed using Imagescope (Aperio v8.2) soft-
ware. The mean immunoreactivity for tumour cells in
central and peripheral tumour regions was calculated for
each tumour.Tissue microarray of primary CRC and CRCLM tissue
A tissue microarray (TMA) consisting of two replicates of
each of three cores from both the centre and peripheral
region of a primary CRC and a synchronous/metachronous
CRCLM from 38 patients was constructed as described
[29]. Immunohistochemistry for 15-PGDH was performed
as described above and each core was scored for 15-PGDH
immunoreactivity by two independent observers based on
the intensity of cytoplasmic staining of tumour cells on a
scale of 1–4 (see Additional file 3: Figure S2). There was
excellent agreement between the observers (κ score 0.94).
The median 15-PGDH score for each tumour region was
derived from a maximum of 12 possible scores (3 cores
each represented twice, independently scored by two
observers) for each tumour area.Human cancer cell culture
HCA-7 human CRC cells were cultured as described
[28]. LIM1863 human CRC cells were obtained from the
Ludwig Institute (Parkville, Melbourne, Australia) and
were cultured in the presence of 5% CO2 in RPMI 1640
with 5% (v/v) foetal calf serum (FCS; Invitrogen). EMT
was induced in LIM1863 cells (Additional file 4: Figure
S3) by 2 ng/ml transforming growth factor β (TGFβ; R&D
Systems Europe Ltd., Abingdon, UK) [30]. MCF-7 human
breast cancer cells were obtained from the European
Collection of Cell Cultures and were cultured in RPMI
1640 (Sigma) with 5% (v/v) FCS. Cells were cultured in
normoxic (20% O2) or hypoxic conditions (1% O2) in a
Sanyo MCO-175 M incubator (Panasonic, Loughborough,
UK) in pre-equillibrated media.
15-PGDH mRNA analysis by quantitative RT-PCR
Total RNA was extracted and reverse transcribed as previ-
ously described [31]. SYBR-Green™ real-time PCR was
performed using an ABI 7700 sequence detection system
using primers for 15-PGDH (forward, 5’-d(TAGTTGGA
TTCACACGCTCAGC); reverse, 5’-d(AAAGCCTGGAC
AAATGGCAT) and the ‘reference’ ribosomal protein gene
36B4, which is unresponsive to hypoxia (forward, 5’-d
(GAAACTCTGCATTCTCGCTTCC); reverse, 5’-d(GATG
CAACAGTTGGGTGCCA) [32]. Levels of 15-PGDH
transcripts were quantified using the 2-ΔCt method [33].
15-PGDH enzyme activity assay
15-PGDH enzyme activity in CRCLM tissue was
measured as described [34]. In brief, tumour cell lysate
was incubated with glutamate dehydrogenase (Sigma) in
the presence of 1 nM [3H]-PGE2 and 1 μmol NAD+
(Sigma). Data are expressed as cpm per 100 mg/protein.
Young et al. BMC Cancer 2013, 13:92 Page 4 of 12
http://www.biomedcentral.com/1471-2407/13/92Any values below the negative control (MCF-7 cell lysate
heat-inactivated at 100°C for 15 minutes) were excluded.
The detailed protocol is provided in Additional file 1:
Methods.
NAD+/NADH assay
Cell and tissue lysates were produced by mechanical dis-
ruption with a Dounce grinder followed by 2 freeze/thaw
cycles (20 minutes at −80°C then 10 minutes at 25°C).
Lysates were immediately passed through a 10 kDa mo-
lecular weight cut-off filter (Biovision, Milpitas, CA,
USA). NAD+ (derived from total NAD minus NADH)
and NADH concentrations were measured in peripheral
and central CRCLM tissue, as well as in LIM 1863Peripheral Central0
20
40
60
80
St
ai
ni
ng
 in
te
ns
ity
COX-2
D
Central
CentralC Radial section
C
P
Radial sectionB
P
C
Periphe0
500
PG
E 2
(p
g/m
g t
ot
al 
pr
ot
ein
)A
1000
1500
Figure 2 Regional differences in PGE2 levels and 15-PGDH immunore
inter-quartile range and range of the PGE2 level in peripheral and central a
in human CRCLM. In each case, a low-power view of the whole section co
centre (C) and periphery (P) of the tumour are marked with a green square
negative control section, for which the primary antibody was omitted (bar
range and range of COX-2 immunoreactivity (D) and 15-PGDH immunorea
Immunohistochemical staining in D) and E) is measured in arbitrary units ohuman CRC cells and in MCF-7 human breast cancer
cells, using an NAD+/NADH assay as per manufacturers’
instructions (Biovision).Immunofluorescence
Immunofluorescence was performed on methanol-fixed
LIM1863 cells, using the same antibodies against 15-PGDH
and E-cadherin used for tissue immunohistochemistry.
Secondary antibodies used were donkey anti-rabbit, Alexa
FluorW 488 (for 15-PGDH) and goat anti-mouse Alexa
FluorW 594 (for E-cadherin; both Invitrogen). Cells were
visualised using a Zeiss Axiostar microscope (Zeiss).
Further detail is provided in Additional file 1: Methods.Peripheral Central
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LIM 1863 cells were cultured in 6-well plates pre-
marked with a 12-square grid for orientation. Recombin-
ant human TGFβ was added for 48 hours before im-
aging. The first 25 adherent colonies, identified by
systematic scanning of the grid, were photographed on
day 2 (Additional file 4: Figure S3) and their position in
the grid recorded for repeat imaging after a further 4 -
days, if still adherent. NIS elements BR2.2 software
(Nikon) was used to measure the area change in every
adherent colony per well. The mean percentage area
change between day 2 and day 6 was calculated and the
mean value was derived from three separate wells per
condition.
Results
PGE2 levels are higher in the central region of CRCLM
relative to peripheral tumour tissue
Initial studies explored whether there was a difference in
PGE2 content between different areas of CRCLM. The
median PGE2 level in central and peripheral regions of
CRCLM was 762 pg/mg protein and 603 pg/mg protein
respectively (Figure 2A). PGE2 levels were increased in
the central region of the tumour compared with the per-
ipheral region in 14 of 20 CRCLMs (Additional file 5:
Figure S4). There was a mean 26% (95% CI 1%-52%)
higher PGE2 level in central tumour regions relative to
paired peripheral tumour tissue (p = 0.04, Wilcoxon rank
sum test).
15-PGDH protein levels are higher in central tumour
regions relative to peripheral CRCLM tissue
Next, we investigated regional expression of the rate-
limiting enzymes for PGE2 synthesis and catabolism.
Representative IHC for COX-2 and 15-PGDH on CRCLM
tissue is shown in Figure 2B-C. A median of 764 810
pixels per region were measured (range: 14,782 –
26,369,364). There was no significant difference between
COX-2 staining intensity in cancer cells between paired
peripheral and central tumour regions in CRCLMs (p =
0.80, Figure 2D and Additional file 5: Figure S4). However,
there was significantly higher 15-PGDH immunoreactivity
in cancer cells in the tumour centre relative to the cancer
cells at the tumour periphery in 13 of 18 CRCLM
(Figure 2E and Additional file 5: Figure S4). There was a
mean 14% (95% CI 3%-27%) increase in 15-PGDH
immunoreactivity in central tumour regions compared
with paired peripheral tissue (p = 0.04). Differential re-
gional expression of 15-PGDH in CRCLM was also
observed using an independent tissue microarray
consisting of tissue cores from the centre and periphery of
38 CRCLM (Additional file 3: Figure S2). Importantly, no
difference in 15-PGDH immunoreactivity between central
and peripheral areas was observed in the tissue microarrayof primary CRCs from the same patients as the CRCLM
(Additional file 3: Figure S2) suggesting that this
phenomenon is specific to CRCLM, as opposed to pri-
mary tumours.
The regional difference in intra-tumoral 15-PGDH
immunoreactivity was confirmed by measurement of
functional 15-PGDH protein levels by the 15-PGDH ac-
tivity assay in the presence of excess substrate and co-
factors. There was a median activity value of 160 cpm/
100 μg protein (range 98–407) in central tumour regions
and 142 cpm/100 μg protein (range 88–323 cpm/100 μg
protein) in peripheral tumour regions (Figure 3A). 15-
PGDH enzyme activity was higher in the central region
of the tumour relative to the periphery in 14 of 20 CRC
liver metastases (Additional file 5: Figure S4). 15-PGDH
activity was 16% (95% CI: 3% – 29%) higher in the cen-
tral tumour area compared with peripheral tumour tis-
sue (p = 0.02).
Given the counter-intuitive observation that PGE2
levels were higher in the central area of CRCLM, in
which expression of the main catabolic enzyme 15-
PGDH was elevated, we performed a series of
experiments, which were designed to investigate the re-
lationship between 15-PGDH expression and levels of
PGE2 in cell-conditioned medium, using HCA-7 human
CRC cells, which constitutively express high levels of
COX-2 and release large quantities of PGE2 into cell cul-
ture medium [28]. By contrast with the CRCLM tissue
studies, we observed that reversible induction of 15-
PGDH expression by acute exposure (less than 24 hours)
to hypoxia (1% O2) was associated with a parallel revers-
ible decrease in PGE2 levels in HCA-7 cell-conditioned
medium, as expected (Additional file 6: Figure S5).
One explanation for high PGE2 levels in the presence
of increased 15-PGDH protein expression in CRCLM,
combined with the contrasting in vitro findings, is that
15-PGDH activity could be compromised by limiting
amounts of NAD+ in a chronic hypoxic tumour micro-
environment, with acute induction of 15-PGDH in
HCA-7 human CRC cells being associated with a reduc-
tion in overall PGE2 production, possibly because there
are sufficient cellular NAD+ stores to maintain efficient
PGE2 catabolism in the acute setting. Therefore, we next
addressed the hypothesis that NAD+/NADH levels are
reduced in the central region of human CRCLM.
NAD+ and NADH levels are lower in the central region of
CRCLM relative to peripheral tumour tissue
The median NAD+ level in central tumour regions was
174 pmol/mg protein (range 5–695 pmol/mg protein)
and 575 pmol/mg protein (range 24–1872 pmol/mg pro-
tein) in the peripheral CRCLM tissue (Figure 3B). We
found that NAD+ levels were significantly lower in the
central tumour area relative to peripheral tissue in 18 of
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Figure 3 Functional 15-PGDH protein levels are increased in
the central area of CRCLM, but NAD+/NADH levels are
decreased, relative to peripheral tumour tissue. A) Maximal
ex vivo 15-PGDH activity in CRCLM tissue in the presence of excess
substrate and co-factors, B) NAD+ levels and C) NADH levels in
peripheral and central CRCLM tissue. In each case, a box and whisker
plot demonstrates the median, inter-quartile range and range
of values.
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mean 59% (95% CI 25%-72%) reduction in NAD+ con-
tent in the tumour centre relative to peripheral tissue in
paired CRCLM tissue (p = 0.01).
The median NADH level in central tumour regions
was 90 pmol/mg protein (range 25–1053 pmol/mg pro-
tein) and 490 pmol/mg protein (range 50–1772 pmol/mgprotein) in the peripheral tumour regions (Figure 3C).
NADH levels were significantly lower in the central
tumour area relative to peripheral tissue in 18 of 20
tumours (Additional file 5: Figure S4). There was a
mean 76% (95% CI 61%-83%) reduction in NADH in the
tumour centre relative to the peripheral area of the
CRCLM (p < 0.01).
Paired data for NAD+ and NADH in central and per-
ipheral tumour tissue were available for 15 CRCLMs.
There was a higher NAD+/NADH ratio in the centre of
the tumour (mean 3.01) compared with the CRCLM
periphery (mean 1.29) in 9 of the 15 tumours but the
median absolute difference in NAD+/NADH ratio be-
tween the centre and the periphery of CRCLMs was not
statistically significant (1.63 [95% CI −0.69-3.66]).
15-PGDH enzyme activity is lower in hypoxic cancer cells
relative to normoxic cancer cells
MCF-7 human breast cancer cells are known to have
significant 15-PGDH activity [35] and hence were used
as a model cancer cell system for initial experiments ex-
ploring the relationship between NAD+ availability and
15-PGDH activity. Using the 15-PGDH activity assay, we
demonstrated that functional 15-PGDH protein expres-
sion was higher in cells cultured in hypoxia than
normoxic conditions (913 vs. 763 cpm/mg protein), but
the difference just failed to reach statistical significance
(p = 0.07). This is consistent with the CRCLM data on
15-PGDH expression in the central region of CRCLMs
and prompted the measurement of the effect of hypoxia
on cellular NAD+ and NADH levels.
In normoxic MCF-7 cells, median NAD+ and NADH
levels were 1087 pmol/mg protein and 1084 pmol/mg
protein respectively compared with median NAD+ and
NADH values of 432 pmol/mg protein and 184 pmol/
mg protein respectively in hypoxic MCF-7 cells
(Figure 4A). A similar reduction was also seen in LIM
1863 human CRC cells, in which cells cultured in
normoxia for 72 hours had median NAD+ and NADH
levels of 160 pmol/mg protein and 164 pmol/mg protein
respectively compared with median values of 50 pmol/
mg protein and 72 pmol/mg protein in cells cultured in
a hypoxic environmrnt for 72 hours (Figure 4B).
Since 15-PGDH is an NAD+ −dependent enzyme and
NAD+ levels are significantly reduced in central tumour
regions and hypoxic tumour cells, inefficient 15-PGDH
enzyme function due to NAD+ depletion in hypoxia
may explain the paradoxical finding of increased PGE2
levels in central regions of CRCLM in the presence of
higher 15-PGDH protein levels.
We therefore tested whether low NAD+ levels in hyp-
oxic cancer cells restricted 15-PGDH activity by measur-
ing ex vivo 15-PGDH activity in MCF-7 cells in the
presence and absence of exogenously added NAD+.
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Figure 4 The effect of hypoxia on NAD+/NADH levels and
endogenous 15-PGDH activity in human cancer cells. A) NAD+
and NADH levels in MCF-7 cells cultured in normoxia (20% O2; N) or
hypoxia (1% O2; H) for 72 hours. Columns and bars represent the
mean and the standard error of the mean (n = 5). B) NAD+ and
NADH levels in LIM1863 cells cultured in normoxia (N) or hypoxia
(H) for 72 hours. Columns and bars represent the mean and the
standard error of the mean (n = 5). C) Ex vivo 15-PGDH activity assay
of MCF-7 cell lysates in the presence or absence of exogenous NAD
+ in the reaction mix. Columns and bars represent the mean and
the standard error of the mean (n = 6).*p < 0.01, **p < 0.01.
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ture (so that 15-PGDH activity is dependent only on the
presence of endogenous NAD+) when testing the lysate
from cells cultured in normoxic conditions was
associated with a significant reduction in 15-PGDH en-
zyme activity compared with cells supplemented with
exogenous NAD+ (Figure 4C). Endogenous 15-PGDH
activity in hypoxic MCF-7 cells was significantly lowerthan 15-PGDH activity in normoxic cells in the absence
of exogenous NAD+ (Figure 4C), thus providing evi-
dence that NAD+ levels may control 15-PGDH activity
and hence affect PGE2 levels depending on the cellular
oxygen tension.
PGE2 promotes EMT in LIM 1863 human CRC cells
It has been described that PGE2 drives EMT of human
CRC cells in vitro [36]. Therefore, we tested the effect of
PGE2 on EMT of COX-2-positive LIM1863 human CRC
cells, which can be used as an in vitro model of EMT in
CRC [37,38]. LIM1863 cells exist in suspension under
standard culture conditions. Upon treatment with re-
combinant human (rh) TGFβ, LIM1863 cells adhere to
tissue culture plastic and grow as distinct colonies of
cells, which have a mesenchymal phenotype (elongated,
spindle-like cells with reduced E-cadherin expression) at
the edge of the colony (Additional file 4: Figure S3). We
used LIM1863 cell colony size following TGFβ treatment
as an objective measure of EMT (Additional file 4:
Figure S3). LIM1863 cells also have the advantage that
they, like many human CRC cell lines, do not synthesize
detectable quantities of PGE2 (data not shown), thereby
allowing us to easily manipulate cell exposure to PGE2.
Using our colony size assay, we confirmed previous
data [39] that EMT in LIM1863 cells is induced by
TGFβ in a concentration-dependent manner (Figure 5).
Exogenous PGE2 (0.1-10 μM), in the presence of low
concentration (0.2 ng/ml) rhTGFβ that induced
LIM1863 cell colony adherence but minimal colony
spreading, promoted EMT in LIM1863 cells in a
concentration-dependent manner (Figure 5). However,
PGE2 did not induce EMT of LIM1863 human CRC
cells in the absence of TGFβ (data not shown).
Hypoxia promotes EMT in LIM 1863 cells
As we had previously demonstrated that hypoxia limits
15-PGDH activity and is associated with increased PGE2
levels in the central region of CRCLMs, we then tested
whether hypoxia promoted EMT and affected 15-PGDH
expression in LIM1863 cells. Hypoxia significantly
promoted EMT of LIM1863 cells compared with
normoxic conditions (Figure 6A). In LIM1863 cell col-
onies cultured in normoxia, cells at the edge of the colony
exhibited reduced membranous E-cadherin expression
(Figure 6B), in keeping with a mesenchymal phenotype as
described [37]. These cells contained less 15-PGDH than
cells in the centre of the colony (Figure 6B). By contrast,
hypoxic LIM 1863 cell colonies did not display any reduc-
tion in 15-PGDH protein content in cells at the edge of
the colony compared with cells in the centre of a colony
(Figure 6B). Observations consistent with these in vitro
findings were made in human CRCLM tissue, in which
there was an inverse relationship between 15-PGDH and
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Figure 5 PGE2 increases TGFβ-induced EMT in LIM1863 human CRC cells. TGFβ induces EMT in LIM1863 human CRC cells in a
concentration-dependent manner. Low concentration TGFβ (0.2 ng/ml) promotes LIM1863 human CRC cell colony adherence, but not spreading,
unlike 2 ng/ml TGFβ, which induces an expansion in adherent colony size. PGE2 drives EMT in a concentration-dependent manner in LIM1863
cells exposed to low concentration TGFβ (0.2 ng/ml). Columns and bars demonstrate the mean and the standard error of the mean (n = 3).
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http://www.biomedcentral.com/1471-2407/13/92E-cadherin immunoreactivity in tumour cells in central
areas of CRCLMs (Figure 6C). In particular, CRC cells that
had lost E-cadherin expression contained higher levels of
immunoreactive 15-PGDH protein consistent with the
observations on hypoxic LIM1863 cells Figure 6C). By
contrast, this relationship was not observed in CRC cells
in the periphery of CRCLMs, in which E-cadherin-low
cells had lower 15-PGDH protein expression than cells
that maintained membranous E-cadherin expression (data
not shown).
Discussion
This is the first study to report regional differences in
the levels of PGE2 and 15-PGDH in human colorectal
tumours. This was made possible by employing a strict
protocol for rapid and uniform processing of orientated
tumour tissue ex vivo. Herein, we report that PGE2 levels
are higher towards the centre of CRCLM compared with
more peripheral cancer tissue. Paradoxically, this was
associated with increased levels of 15-PGDH protein at
the centre of CRCLM. However, we demonstrated that
the 15-PGDH activity level in the centre of CRCLM is
reduced and is associated with low NAD+/NADH levels.
In vitro studies confirmed that NAD+ availability drives
15-PGDH activity in human CRC cells. We believe that
consideration of regional differences in PGE2 metabolism
and micro-environmental influences on PGE2 metabolism
related to enzyme co-factor availability and/or hypoxia is a
paradigm shift in the field of eicosanoid cancer research
and is consistent with latest understanding of genetic and
epigenetic intra-tumoral heterogeneity [14,40]. Consider-
ation of intra-tumoral differences in PGE2 metabolism is
essential for development of optimal anti-CRC therapy
aimed at the COX-PGE2-15-PGDH axis.
Our data highlight significant differences between
findings in human cancer tissue ex vivo and experimen-
tal observations using CRC cells in vitro. Although wepropose that differences in 15-PGDH activity in cancer
tissue compared with cultured CRC cells may account
for the contrasting relationship between 15-PGDH ex-
pression and PGE2 levels in CRCLM tissue versus cell-
conditioned medium, we cannot completely rule out that
inadvertent stimulation of PGE2 synthesis ex vivo oc-
curred. Avoidance of possible artefactual changes in tis-
sue eicosanoid levels ex vivo will only be possible with
other techniques such as MALDI-MS for measurement
of PG distribution in frozen tissue sections [41].
The tissue microarray comparison of regional differences
in 15-PGDH immunoreactivity between CRCLM and the
paired primary CRC suggests that 15-PGDH expression,
and hence PGE2 metabolism, in CRCLM differs from that
in the primary CRC, from which the CRCLM were derived.
This finding is consistent with recent data describing
significant genetic differences between primary CRC and
synchronous liver metastasis [40]. Local factors specific to
CRCLM may, at least partly, explain regional 15-PGDH
expression in CRCLM and the contrast with observations
from previous studies of 15-PGDH expression in primary
CRCs [12].
NAD+ and NADH levels were both significantly lower
in central rather than peripheral CRCLM tissue, compat-
ible with depletion of the cellular NAD(H) pool. The
NAD+/NADH ratios that we observed in human
CRCLM tissue are similar to previous studies that have
measured tissue NAD(H) levels by the same cycling
assay [42]. However, absolute levels of NAD+ and
NADH were low compared with other tissues [42]. One
testable hypothesis is that the NAD(H) pool is depleted
because of increased NAD-consuming enzyme activity
in CRC cells. Consistent with this notion, sirtuins such
as SIRT1 and poly-(ADP ribose) polymerase expression
and activity are increased in cancer tissue [43]. In
particular, SIRT1 expression and activity are increased in
human hepatoma and fibrosarcoma cells in vitro [26].
normoxia hypoxia
% area increase 
from day 2 
2 ng/ml TGF
normoxic 
0.2 ng/ml TGF
normoxic 
0.2 ng/ml TGF
hypoxic 
* 
A 
B 
C 
15-PGDH
20µm
E-cadherin
15-PGDHE-cadherin
E-cadherin positive
low 15-PGDH
E-cadherin negative
high15-PGDH
Figure 6 Hypoxia promotes EMT of LIM1863 human CRC cells. A) EMT of LIM1863 human CRC cells cultured in either normoxia (20% O2) or
hypoxia (1% O2) in the presence of 0.2 ng/ml TGFβ. Positive control cells underwent EMT in the presence of 2 ng/ml TGFβ. *p = 0.02 for the
difference from normoxic cells cultured in the presence of 0.2 ng/ml TGFβ (n = 3). B) Dual immunofluorescence for E-cadherin (red) and 15-PGDH
(green) on LIM1863 human CRC cells six days after addition of TGFβ. DAPI was used for nuclear visualisation (blue). LIM 1863 human CRC cells
were cultured in the presence of 0.2 ng/ml TGFβ for six days (normoxia) or were transferred to hypoxic conditions (1% O2) on day two. In
normoxic conditions, E-cadherin-negative cells at the edge of the colony did not express 15-PGDH (white arrows). However, E-cadherin-low cells
at the edge of hypoxic colonies were still 15-PGDH-positive (yellow arrows). C) Immunohistochemistry for 15-PGDH and E-cadherin on sequential
sections of a representative central region of CRCLM. Images taken from representative areas of stained sections show an inverse relationship
between E-cadherin and 15-PGDH immunoreactivity such that 15-PGDH expression was high in E-cadherin-low cells and vice versa.
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http://www.biomedcentral.com/1471-2407/13/92One weakness of our study is that we do not have dir-
ect evidence that the central area of CRCLMs that we
studied were hypoxic. However, there is substantial in-
direct evidence that regional hypoxia exists in tumours
including CRCLMs [19-21]. Importantly, the regional
difference in functional 15-PGDH protein levels in
CRCLMs was not mirrored in primary CRC. Central
tumour necrosis is more common in CRCLMs than pri-
mary CRC tumours and implies greater degrees of hyp-
oxia in the central regions of CRCLMs, which could
account for differential 15-PGDH expression in meta-
static tumours. This observation, and the fact that
elevated 15-PGDH in CRC cells in the centre of
CRCLMs is likely inactive secondary to NAD+ defi-
ciency, help to reconcile our data with the existing lit-
erature, which, in general (but not exclusively), implies
that 15-PGDH has tumour suppressor activity [12].
Roberts et al. have reported that acute hypoxia (16 -
hours) did not alter 15-PGDH protein expression in HT-
29 human CRC cells, despite an increase in PGE2 levels
believed to be secondary to COX-2 induction [25]. It is
possible that CRC cell line-specific differences in
hypoxia-induced gene expression and NAD+ availability
explain the experimental variability in in vitro models.
Nevertheless, our data highlight that it is crucial to con-
firm the relevance of in vitro observations in tissue ex-
pression studies, which take into account potential
micro-environmental influences.
TGFβ-induced attachment and spreading of LIM1863
human CRC cell colonies allowed us to develop a novel
semi-quantitative measure of EMT based on an established
model [38]. Using this assay, we have provided support
for previous observations that PGE2 drives EMT of CRC
and other human cancer cells in vitro, which were based
on down-regulation of E-cadherin expression, light-
microscopic phenotype changes in adherent cells and
cell motility assays [5,36,44,45].
We have contributed to emerging evidence that hyp-
oxia drives EMT [46]. Interestingly, we observed that
15-PGDH expression was maintained in hypoxic TGFβ-
induced LIM1863 human CRC cell colonies in vitro and
CRC cells in the centre of CRCLMs that had an ‘EMT
(E-cadherin-low) phenotype’. This is consistent with our
observations that hypoxia induces 15-PGDH in other
CRC cell lines in vitro and that 15-PGDH levels are
higher in the centre rather than the periphery of
CRCLMs. One testable hypothesis is that hypoxia
inhibits β-catenin-related signaling [47], which could
lead to de-repression of 15-PGDH [48]. Further studies
are required to understand the rather counter-intuitive
finding that the main rate-limiting catabolic enzyme for
PGE2 inactivation is elevated in a tumour microenviron-
ment, in which cell survival would be potentiated by
PGE2. These studies should always take into accountNAD+ co-factor availability and measure levels of other
lipid mediators, which have anti-proliferative activity,
that are also potential substrates for 15-PGDH such as
lipoxins [11].
Previous in vitro studies have demonstrated that Snail,
one of the key transcription factors in EMT, represses
15-PGDH expression in CRC cells via direct binding to
conserved E-box elements in the 15-PGDH promoter re-
gion [5]. However, to our knowledge, the effect of hyp-
oxia on human 15-PGDH gene expression has not been
formally assessed. The human 15-PGDH gene promoter
contains multiple ETS, AP-1 and CREB binding sites
[49], although no hypoxia-responsive elements for direct
hypoxia-inducible factor binding are evident. Therefore,
a valid, testable hypothesis is that 15-PGDH is a
hypoxia-inducible gene in CRC via ETS-dependent tran-
scriptional up-regulation, which is recognised for several
hypoxia-inducible genes [50].
Conclusions
In summary, we have demonstrated that there are sig-
nificant regional differences in PGE2 metabolism in
human CRCLM. Relative lack of NAD+ availability in
the central tumour micro-environment is a plausible ex-
planation for the difference in relationship between
PGE2 content and 15-PGDH expression in tumour tissue
compared with cultured human CRC cells in vitro. A re-
ciprocal relationship between the PGE2 level and 15-
PGDH expression is lost in hypoxic conditions in the
context of CRC EMT. It will be essential to measure 15-
PGDH function rather than just protein levels in future
studies of PGE2 availability and the role of 15-PGDH
during human carcinogenesis.
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